The acquisition will allow Eurolife to consolidate its position as a prominent player in the segment and expand its FFS infusion manufacturing capacity, Eurolife Healthcare said in a statement.
The company, however, did not provide any financial details of the proposed acquisition.
"Eurolife is totally committed to making significant investments in the acquired facilities, in order to expand capacity to feed our flourishing FFS infusions business both locally and globally," Eurolife Healthcare CEO Sandeep Toshniwal said.
Following the close of the transaction, Eurolife Healthcare will have a pan-India FFS infusions manufacturing presence in Maharashtra, Tamil Nadu and Uttarakhand, the company said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
